Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba, +8

JAMA Oncology

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto, +126

The Lancet Oncology

MedicinePathologyImmune Checkpoint InhibitorCancer TreatmentOncology +3

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

Toshiaki Takahashi, Takeharu Yamanaka, Takashi Seto, +13

The Lancet Oncology

Radiation MedicineRadiation TherapyMedicineClinical Radiation OncologyOncology +4

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

Koji Haratani, Hidetoshi Hayashi, Taro Tanaka, +19

Annals of Oncology

Tumor Immune MicroenvironmentCancer ImmunosurveillanceMedicineImmunologyTumor Immunity +9

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

Junko Tanizaki, Koji Haratani, Hidetoshi Hayashi, +10

Journal of Thoracic Oncology

Biomarker (Medicine)Prognostic BiomarkersOncologyMedicineBiomarker Target +7

FOXQ1 Is Overexpressed in Colorectal Cancer and Enhances Tumorigenicity and Tumor Growth

Hiroyasu Kaneda, Tokuzo Arao, Kaoru Tanaka, +11

Cancer Research

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Kimio Yonesaka, Koji Haratani, Shiki Takamura, +20

Clinical Cancer Research

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

Junko Tanizaki, Isamu Okamoto, Takafumi Okabe, +10

Clinical Cancer Research

mTOR Signal and Hypoxia-Inducible Factor-1α Regulate CD133 Expression in Cancer Cells

Tokuzo Arao, Kaoru Tanaka, Hiroyasu Kaneda, +8

Cancer Research

Tumor BiologyMtor SignalSignaling PathwayCell RegulationMedicine +12

Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection

Yasuhiro Kidera, Hisato Kawakami, Tsutomu Sakiyama, +13

PLoS ONE